R1 Therapeutics Raises $77.5 Million in Series A Funding
R1 Therapeutics, a biotechnology company based in Redwood City, California, has successfully raised $77.5 million in a Series A funding round. The company is focused on developing innovative therapeutics for patients suffering from kidney disease.
Funding Details
The funding round, which took place on March 17, 2026, was led by prominent investors Abingworth, F-Prime, and DaVita Venture Group. Additional participation came from Curie.Bio, SymBiosis, and U.S. Renal Care. This substantial investment underscores the confidence investors have in R1 Therapeutics' potential to make significant advancements in the field of kidney disease treatment.
Leadership Team
R1 Therapeutics was co-founded by Krishna Polu, who serves as the President and CEO, and Mary Smith, the Chief Operating Officer. Their leadership is central to the company's mission of creating category-defining therapeutics. Polu and Smith bring extensive experience in biotechnology and healthcare, which is instrumental in driving the company's growth and innovation.
Strategic Use of Funds
The newly acquired funds are expected to be directed towards accelerating the development of R1 Therapeutics' pipeline of products aimed at treating kidney disease. This could include expanding their research and development efforts, increasing their team of scientists, and potentially advancing clinical trials. While specific details on the use of funds were not disclosed, these areas are likely priorities given the company's focus and the nature of the investment.
The Road Ahead
With this significant financial backing, R1 Therapeutics is well-positioned to enhance its research capabilities and bring new treatments to market. As the company continues to innovate in the field of kidney disease, it remains committed to improving patient outcomes and addressing unmet medical needs. The support from leading investors indicates strong industry confidence in R1 Therapeutics' approach and future prospects.
This Series A funding marks a pivotal step for R1 Therapeutics as it seeks to establish itself as a key player in the biotechnology landscape, particularly in the area of kidney disease therapeutics. As the company advances, stakeholders will be watching closely to see how it leverages this investment to achieve its goals.